Science Current Events | Science News | Brightsurf.com
 

FDG-PET Imaging Clearly Predicts Lung Cancer Patients' Response to Chemotherapy

May 10, 2007
Repeating Molecular Imaging Studies Provides Valuable Information for Better Patient Care, Say Researchers in May Journal of Nuclear Medicine

RESTON, Va.—An earlier indication of whether chemotherapy benefits non-small cell lung cancer patients—provided by positron emission tomography (PET) imaging—can guide doctors in offering them better care, according to researchers in the May Journal of Nuclear Medicine.

"Our study demonstrates that patients who respond to chemotherapy can be identified early in the course of their treatment, and these patients will generally exhibit prolonged overall survival," explained Claude Nahmias, professor of radiology and medicine at the University of Tennessee Medical Center in Knoxville. "Although we studied a relatively small number of patients—and our results should be interpreted with caution—it is clear that a repeat PET study with the radiotracer fluorodeoxyglucose (FDG) at the end of the first cycle of chemotherapy would allow the identification of those patients for whom the therapy was futile," he said. "The ability to provide an early indication of therapeutic response has the potential to improve patient care by identifying those patients who do not benefit from their current treatment," explained Nahmias. "Patients would benefit from either having chemotherapy and its associated toxic side effects stopped or going on to a different, and hopefully more adequate, therapeutic approach," added the co-author of "Time Course of Early Response to Chemotherapy in Non-Small Cell Lung Cancer Patients With 18F-FDG PET/CT."

Non-small cell lung cancer is the most common type of lung cancer, usually growing and spreading more slowly than small cell lung cancer. -Lung cancer is the second most common cancer and the most common cause of cancer-related death in both men and women in the United States. In 2007, about 213,380 new cases of lung cancer (both small cell and non-small cell) are expected in the United States, and about 160,390 people will die of this disease. For most patients with non-small cell lung cancer, current treatments do not cure the cancer.

"With non-small cell lung cancer—since the relatively modest increase in survival must be balanced against the toxicity of the chemotherapeutic treatment—the case for monitoring therapeutic response is especially compelling," said Nahmias. "To assess the response to chemotherapy in patients with advanced non-small cell lung cancer, all of the studies published thus far have evaluated the patients at one, or at most two, time points after the initiation of chemotherapy," said Nahmias. "In our study, we evaluated 15 patients weekly—for seven weeks—as they started their chemotherapy regiment. In spite of the persuasive findings of several studies investigating PET for monitoring response to cancer therapy, until now no published reports have clearly demonstrated that PET results were used to alter treatment," he noted.

PET is a powerful molecular imaging procedure that noninvasively demonstrates the function of organs and other tissues. When PET is used to image cancer, a radiopharmaceutical (such as FDG, which includes both a sugar and a radionuclide) is injected into a patient. Cancer cells metabolize sugar at higher rates than normal cells, and the radiopharmaceutical is drawn in higher amounts to cancerous areas. PET scans show where FDG is by tracking the gamma rays given off by the radionuclide tagging the drug and producing three-dimensional images of their distribution within the body. PET scanning provides information about the body's chemistry, metabolic activity and body function.

"Our result—that PET studies one and three weeks after initiation of cancer therapy can predict success or failure of the therapy—should be validated in a larger study in which patients are enrolled with the intention of applying it in patient management," said Nahmias. He added, "I am forever grateful to all the patients who came back week after week to undergo our PET scans."

"Time Course of Early Response to Chemotherapy in Non-Small Cell Lung Cancer Patients With 18F-FDG PET/CT" appears in the May issue of the Journal of Nuclear Medicine, which is published by SNM, the world's largest molecular imaging and nuclear medicine society. Other co-authors are Wahid T. Hanna, Misty J. Long, Karl F. Hubner and David W. Townsend, departments of Medicine and Radiology, University of Tennessee, Knoxville, and Lindi M. Wahl, Department of Applied Mathematics, University of Western Ontario, London, Canada.

Society of Nuclear Medicine


Related Lung Cancer Current Events and Lung Cancer News Articles


Long telomere length associated with increased lung cancer risk
A large-scale genetic study of the links between telomere length and risk for five common cancers finds that long telomeres are associated with an increased risk of lung adenocarcinoma.

Overcoming why a new treatment is resisted by lung cancer
A promising agent for the treatment of cancer has so far had little effect on the most common lung tumours, but new research from The University of Manchester has suggested how this resistance might be overcome.

'Pill on a string' could help spot early signs of cancer of the gullet
A 'pill on a string' developed by researchers at the University of Cambridge could help doctors detect oesophageal cancer - cancer of the gullet - at an early stage, helping them overcome the problem of wide variation between biopsies, suggests research published today in the journal Nature Genetics.

Uncovering the secrets of immune system invaders
The human immune system is a powerful and wonderful creation.

Annual low-dose CT screening safe and reliable for identifying pre-cancers
An annual exam using a key imaging technology could spare patients with lung nodules from unnecessary tests and surgery, while identifying the cases where the nodules are likely to become cancerous, according to a new study by researchers at Icahn School of Medicine at Mount Sinai (ISMMS) and published online today in journal Radiology.

Millions of smokers may have undiagnosed lung disease
More than half of long-term smokers and ex-smokers who are considered disease-free because they passed lung-function tests have respiratory-related impairments when more closely evaluated with lung imaging, walking and quality-of-life tests.

CT allows nonsurgical management of some lung nodules
People who have nonsolid lung nodules can be safely monitored with annual low-dose computed tomography (CT) screening, according to a new study published online in the journal Radiology.

Future oncology explores role of biomarkers and next generation sequencing
Highlighting the seismic shift in cancer research and treatment that is underway due to biomarkers and next generation sequencing, a special issue of Future Oncology offers multiple review articles summarizing the opportunities presented by improvements in molecular testing and analysis.

Tests to gauge genetic risks for prostate cancer now are feasible
Men with an elevated, genetically inherited risk for prostate cancer could be routinely identified with a simple blood or urine test, scientists at UC San Francisco and Kaiser Permanente Northern California have concluded, potentially paving the way to better or earlier diagnosis.

Comorbid conditions associated with worse lung cancer survival
Lung cancer patients with comorbid conditions such as chronic obstructive pulmonary disease, diabetes, or congestive heart failure had a higher risk of death than lung cancer patients without comorbid conditions.
More Lung Cancer Current Events and Lung Cancer News Articles

Non-Small Cell Lung Cancer: Across the Continuum of Care

Non-Small Cell Lung Cancer: Across the Continuum of Care
by Asante Communications, LLC


This Clinical Resource Tool is structured around consensus statements developed by the Non-Small Cell Lung Cancer (NSCLC) Working Group, a panel of oncologists with particular expertise in the multidimensional care of patients with advanced lung cancer. Using a modified Delphi process, the NSCLC Working Group has consolidated published evidence and expert clinical experience on critical issues pertaining to the comprehensive assessment of patients with advanced NSCLC, formulation of appropriate treatment regimens, implementation of maintenance therapy, and therapeutic alliances among pathologists, oncologists, and pulmonologists. The consensus statements and accompanying resources are intended as a practical companion to current guidelines, helping clinicians individualize best-practice...

Living with Lung Cancer--My Journey

Living with Lung Cancer--My Journey
by Thomas E. Cappiello (Author)


On October 5 2007, Thomas Cappiello was diagnosed with inoperable Stage IIIA locally-advanced adenocarcinoma (Non-Small Cell Lung Cancer), an incurable disease. This book is the inspirational story of how he beat the odds and survived and thrived in the face of this devastating illness. This book is for patients and caregivers who want to know what life is like after getting a cancer diagnosis. The story is about overcoming the emotional turmoil and devastation of a cancer diagnosis, dealing with the disease, and making choices. Most of all, it's about living a full life each day. Cancer patients suddenly realize that time is a precious gift from God and there is no time to waste. By telling his story Cappiello seeks to inspire cancer patients to fight hard and live, with whatever time...

You Can Beat Lung Cancer: Using Alternative/Integrative Interventions

You Can Beat Lung Cancer: Using Alternative/Integrative Interventions
by Carl O. Helvie (Author)


Can you overcome lung cancer without harsh chemicals, surgery and debilitation? Are alternative interventions effective? Why do conventional physicians not use them? Can you prevent cancer recurrences and live into old age without chronic diseases and prescribed medications? This book answers these and other questions. This is one of the most comprehensive books available on alternative treatments for lung cancer. It explains the treatments used successfully by a health professional/cancer survivor of 36 years and by some of the leading medical and health practitioners currently in the field. G. Edward Griffin, Author of World Without Cancer, The Politics of Cancer Therapy, and other books and films. Recipient of the Telly Award for Excellence in Television Production. President of...

Lung Cancer: Myths, Facts, Choices--and Hope

Lung Cancer: Myths, Facts, Choices--and Hope
by Claudia I. Henschke (Author), Peggy McCarthy (Author), Sarah Wernick (Contributor)


An authoritative book with new lifesaving strategies for those at risk and those already diagnosed. Lung cancer kills more women than breast cancer, more men than prostate cancer. This authoritative book presents new lifesaving strategies for those already diagnosed and those at risk (including ex-smokers).

Lung cancer is deadly because it's usually found late. Dr. Claudia Henschke's groundbreaking research on early diagnosis, published in Lancet, made headlines worldwide. Now, for the first time, she offers specific recommendations based on her latest findings: who needs to be checked and how to get tested.

People with lung cancer often are told, "Nothing can be done." Not so! Dr. Henschke and coauthor Peggy McCarthy, a leading patient advocate, provide...

Johns Hopkins Patients' Guide To Lung Cancer

Johns Hopkins Patients' Guide To Lung Cancer
by Justin F. Klamerus (Author), Julie R. Brahmer (Author), David S Ettinger (Author)


Johns Hopkins Patients' Guide to Lung Cancer is a concise, easy-to-follow “how to” guide that puts you on the path to wellness by explaining lung cancer treatment from start to finish. It guides you through the overwhelming maze of treatment decisions, simplifies the complicated schedule that lies ahead, and performs the task of putting together your plan of care in layman's terms. Empower yourself with accurate, understandable information that will give you the ability to confidently participate in the decision making about your care and treatment.

Lung Cancer Causes, Symptoms,  Stages & Treatment Guide: Cure Lung Cancer With  A Positive Outlook

Lung Cancer Causes, Symptoms, Stages & Treatment Guide: Cure Lung Cancer With A Positive Outlook
by Danielle Dixon


This book contains proven steps and strategies on how to prevent, treat and fight cancer.

Cancer has long been closely associated with death, low quality of life, and financial difficulties. With all the complications it causes, lives it takes, and people it subjects to suffering, cancer is definitely a difficult disease.

Lung cancer is one of the leading causes of cancer deaths worldwide. Different risk factors have been attributed to its development- with genetics and environmental influences playing a major role. The diversity of its causes makes its treatment all the more difficult, which makes identification of causes essential to its management. The recognition of symptoms and diagnosis early in the course of the disease most frequently leads to good...

How to Survive Lung Cancer - A Practical 12-Step Plan

How to Survive Lung Cancer - A Practical 12-Step Plan
by Michael Lloyd (Author)


Written by a lung cancer survivor who understands what it takes to beat the odds, this book offers unparalleled hope and direction for anyone facing this illness. It is filled with specific exercises and techniques to promote healing and reverse side effects by taking a pro-active approach in helping to restore your mind, body and spirit to an optimum state of health. Endorsed by a Lung Cancer Specialist and Associate Professor at Harvard Medical School, this book combines what the doctors tell you with critical information they don't tell you. Visit www.SurviveLungCancer.com for chapter summaries.

Lung Cancer: Diagnosis and Management

Lung Cancer: Diagnosis and Management
by CME Resource/NetCE


The purpose of this course is to address the various aspects of diagnosis, treatment, disease management and appropriate patient care for healthcare professionals caring for patients with lung cancer. In addition, members of the public may use this course to enhance their personal knowledge of the subject matter presented.

Upon completion of this course, you should be able to:
1. Discuss the risk factors and incidence of lung cancer.
2. Explain the pathophysiology of lung cancer.
3. Identify the signs and symptoms of lung cancer.
4. Discuss the various tests used to diagnose lung cancer.
5. Describe the lung cancer classification and staging system.
6. Discuss the treatment options available to the patient with lung cancer, including potential...

Principles and Practice of Lung Cancer: The Official Reference Text of the International Association for the Study of Lung Cancer (IASLC)

Principles and Practice of Lung Cancer: The Official Reference Text of the International Association for the Study of Lung Cancer (IASLC)
by Harvey I. Pass MD (Editor), David P. Carbone MD PhD (Editor), David H. Johnson MD (Editor), John D. Minna MD (Editor), Giorgio V. Scagliotti MD (Editor), Andrew T. Turrisi III MD (Editor)


Thoroughly revised and updated, this Fourth Edition is the most comprehensive, current reference on lung cancer, with contributions from the world's foremost surgeons, radiation oncologists, medical oncologists, pulmonologists, and basic scientists. Coverage includes complete information on combined modality treatments for small cell and non-small cell lung cancer and on complications of treatment and management of metastases. Emphasis is also given to early detection, screening, prevention, and new imaging techniques. This edition has expanded thoracic oncology chapters including thymus, mesothelioma, and mediastinal tumors, more detailed discussion of targeted agents, and state-of-the-art information on newer techniques in radiotherapy. Other highlights include more international...

100 Questions  &  Answers About Lung Cancer (100 Questions and Answers)

100 Questions & Answers About Lung Cancer (100 Questions and Answers)
by Joan H. Schiller (Author), Amy Cipau (Author)


EMPOWER YOURSELF! No one with lung cancer needs to be alone in their fight against this disease. 100 Questions & Answers About Lung Cancer, Third Edition, guides patients and their families through diagnosis, treatment and survivorship. Providing both the doctor’s and patient’s point of view, this book is a complete guide to understanding treatment options, post-treatment quality of life, sources of support, and much more. Through 100 Questions & Answers About Lung Cancer, Third Edition, expert authors use their experiences with patients to provide support and hope to the tens of thousands of people coping with lung cancer.

© 2015 BrightSurf.com